الثلاثاء 9 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment | Merck Serono | Ongoing | N/A | 4 | EMR200104-534 | King Fahad University Hospital (Al-Khobar), alhabib |
| Observational Prospective STudy In Management of 1st line KRAS Wildtype mCRC with Erbitux™ (Cetuximab)- OPTIM1SE | Merck Serono | Ongoing | Erbitux (Cetuximab) | 4 | EMR062202-561 | King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), Prince Sultan Military Medical City (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Postoperative Analgesic Effect ofDexmedetomidine as an Adjunct to Ropivacaine Administration in Wound Infiltration for Modified Radical Mastectomy- A Randomized controlled Trial | King Abdullah Medical City, Makkah | Ongoing | DEXMEDETOMIDINE | 2 | 14-119 | King Abdullah Medical City (Makkah) |
| AWARE-AMAC (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation in Asia pacific, Middle-east and African Countries (AWARE-AMAC): A noninterventional study to collect data on the management and clinical impacts of chronic urticaria in patients refractory to H1-antihistamine therapy | Novartis | Ongoing | N/A | 4 | E3401 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| Non transfusion dependent Thalassemia Drug Registry | Novartis | Ongoing | Exjade (Deferasirox) | 4 | E2422 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Khalid University Hospital (Riyadh) |
| CogniPlus Study assessing Cognitive performance plus Physical activity in patients with Relapsing-Remitting MS under treatment with Betaferon® | Bayer | Ongoing | Betaferon | 4 | 16036 | King Fahad Hospital (Madinah), Security Forces Hospital (Riyadh), Aseer Central Hospital, King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), King Abdul Aziz Specialist hospital (Taif), King Fahad Specialist Hospital (Dammam) |
| International Registry to assess mEdical Practice withlOngitudinal obseRvation for Treatment of Heart Failure(REPORT-HF) | Novartis | Ongoing | N/A | 4 | 2401 | King Fahad Specialist Hospital (Dammam) |
| A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | Novartis | Ongoing | LEE011 (Ribociclib) | 3 | CLEE011E2301 | King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) | KAIMRC | Ongoing | Carglumic acid | 3 | IIT-OE-2013-001 | King Abdulaziz Medical City NG (Riyadh)_ King Fahad Medical City (Riyadh) |
| A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | Bayer | Ongoing | Sorafenib | 3 | BAY43-9006/14295 | King Faisal Specialist Hospital and Research Center (Riyadh) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.